There are 2789 resources available
1467P - POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer
Presenter: Dirk Arnold
Session: ePoster Display
1468P - POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
Presenter: Talia Golan
Session: ePoster Display
1294P - 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC
Presenter: Filippo Dall'Olio
Session: ePoster Display
1295P - Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone
Presenter: Mathilde Bureau
Session: ePoster Display
1296P - Immune checkpoint inhibitors with or without bone targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio
Presenter: Alberto Bongiovanni
Session: ePoster Display
1401P - Findings and survival comparison of EUS and PET-TC restaging applied to esophageal and gastric adenocarcinomas
Presenter: Victor Amezcua Hernandez
Session: ePoster Display
1402P - Gastroesophageal cancer treatment patterns in Europe and the United States: An exploratory analysis using population-based cancer registry data
Presenter: Francesco Giusti
Session: ePoster Display
1404P - Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial
Presenter: Junsheng Wang
Session: ePoster Display